Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: Dramatic and durable symptomatic benefit from hepatic artery embolization, a case report

Medical Oncology

Volumn 19, Issue 3, 2002, Pages 181-187

  Case, C C ^a   Wirfel, K ^b   Vassilopoulou Sellin, Rena ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hepatic artery embolization; Neuroendocrine tumors; Secretory diarrhea; VIPoma

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER STAGING; CASE REPORT; CLINICAL EXAMINATION; DIARRHEA; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; PRIORITY JOURNAL; VIPOMA;

EID: 0036434751     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/mo:19:3:181     Document Type: Article

References (41)

1. Verner, J.V. and Morrison, A.B. (1958). Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am. J. Med. 9, 374-380.
2. Bloom, S.R., Polak, J.M. and Pearse, A.G. (1973). Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet 2, 14-16.
3. Modlin, I.M., Lewis, J.J., Ahlman, H., Bilchik, A.J. and Kumar, R.R. (1993). Management of unresectable malignant endocrine tumors of the pancreas. Surg. Gynecol. Obstet. 176, 507-518.
4. Maton, P.N., Gardner, J.D. and Jensen, R.T. (1989). Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig. Dis. Sci. 34, 285-395.
5. Smith, S.L., et al. (1998). Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 124, 1050-1055.
6. Mekhjian, H.S. and O'Dorisio, T.M. (1987). VIPoma syndrome. Semin. Oncol. 14, 282-291.
7. Moertel, G.C., et al. (1994). The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann. Intern. Med. 120, 302-309.
8. Arcenas, A.G., Ajani, J.A., Carrasco, C.H., Levin, B. and Wallace, S. (1995). Vascular occlusive therapy of pancreatic endocrine tumors metastatic to the liver, in Endocrine Tumors of the Pancreas: Recent Advances in Research and Management (Mignon, M. and Jensen, R.T., eds), pp439-446, Karger, Basel.
9. Krausz, Y., et al. (1998). Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Am. J. Gastroenterol. 93, 66-70.
10. Nguyen, H.N., et al. (1999). Long-term survival after diagnosis of hepatic metastatic VIPoma: Report of two cases with disparate courses and review of therapeutic options. Dig. Dis. Sci. 44, 1148-1155.
11. Yeh, C.N., Chen, M.F. and Chen, T.C. (2001). Surgical treatment of pancreatic vasoactive intestinal polypeptide-secreting tumor: A case report. Hepato-gastroenterology 48, 421-423.
12. Rood, R.P., DeLellis, R.A., Dayal, Y. and Donowitz, M. (1988). Pancreatic cholera syndrome due to a vasoactive intestinal polypeptide-producing tumor: Further insights into the pathophysiology. Gastroenterology 94, 813-818.
13. Barraclough, M.A. and Bloom, S.R. (1979). Vipoma of the pancreas: Observations on the diarhrhea and circulatory disturbances. Arch. Intern. Med. 139, 467-471.
14. Soga, J. and Yakuwa, Y. (1998). Vipoma/diarrheogenic syndrome: A statistical evaluation of 241 reported cases. J. Exp. Clin. Cancer Res. 17, 389-400.
15. Hammond, P.J., Gilbey, S.G., Wynick, D. and Bloom, S.R. (1993). Glucagonoma, VIPoma, somatostatinoma, other hormones, and nonfunctional tumors, in Endocrine Tumors (Mazzaferri, E. and Samaan, N.A., eds), pp457-483, Blackwell Scientific, Cambridge.
16. Brentjens, R. and Saltz, L. (2001). Islet cell tumors of the pancreas. The medical oncologist's perspective. Surg. Clin. North Am. 81, 527-542.
17. Kvols, L.K., et al. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J. Biol. Med. 5, 505-518.
18. Lamberts, S.W., van der Lely, A.J., de Herder, W.W. and Hofland, L.J. (1996). Octreotide. N. Engl. J. Med. 334, 246-254.
19. Clements, D. and Elias, E. (1985). Regression of metastatic VIPoma with somatostatin analogue SMS 201-995. [letter]. Lancet 1, 874-875.
20. Kraenzlin, M.E., Ch'ng, J.L., Wood, S.M., Carr, D.H. and Bloom, S.R. (1985). Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88, 185-187.
21. Venkatesh, S., Vassilopoulou-Sellin, R. and Samaan, N.A. (1989). Somatostatin analogue: Use in the treatment of VIPoma with hypercalcemia. Am. J. Med. 87, 356-357.
22. Gagel, R.F., et al. (1976). Streptozocin-treated Verner-Morrison syndrome: Plasma vasoactive intestinal peptide and tumor responses. Arch. Intern. Med. 136, 1429-1435.
23. Moertel, C.G., Lefkopoulo, M., Lipsitz, S., Hahn, R.G. and Klaassen, D. (1992). Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N. Engl. J. Med. 326, 519-523.
24. Eriksson, B. and Oberg, K. (1993) An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol. 32, 203-208.
25. Cheng, P.N. and Saltz, L.B. (1999). Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86, 944-948.
26. Markowitz, J. (1952). The hepatic artery. Surg. Gynecol. Obstet. 95, 644-646.
27. Chuang, V.P. and Wallace, S. (1981). Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 140, 51-58.
28. Wallace, S., Charnsangavej, C., Carrasco, C.H. and Bechtel, W. (1984). Infusion embolization. Cancer 54(Suppl.), 2751-2765.
29. Carrasco, C.H., Chuang, V.P. and Wallace, S. (1983). Apudomas metastatic to the liver: Treatment by hepatic artery embolization. Radiology 149, 79-83.
30. Venook, A.P. (1999). Embolization and chemoembolization therapy for neuroendocrine tumors. Curr. Opin. Oncol. 11, 38-41.
31. Marlink, R.G., Lokich, J.J., Robins, J.R. and Clouse, M.E. (1990). Hepatic arterial embolization for metastatic hormone-secreting tumors. Technique, effectiveness, and complications. Cancer 65, 2227-2232.
32. Ruszniewski, P., et al. (1993). Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71, 2624-2630.
33. Perry, L.J., Stuart, K., Stokes, K.R. and Clouse, M.E. (1994). Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116, 1111-1116.
34. Ajani, J.A., et al. (1988). Islet cell tumors metastatic to the liver: Effective palliation by sequential hepatic artery embolization. Ann. Intern. Med. 108, 340-344.
35. Carrasco, C.H., et al. (1986). The carcinoid syndrome: Palliation by hepatic artery embolization. Am. J. Roentgenol. 147, 149-154.
36. Drougas, J.G., et al. (1998). Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am. J. Surg. 175, 408-412.
37. Bierman, H.R., Byron, R.L. and Kelly, R.H. (1951). Studies on the blood supply of tumors in man: Arteriography in vivo. J. Natl. Cancer Inst. 12, 107-131.
38. Breedis, C. and Young, G. (1954). The blood supply of neoplasms in the liver. Am. J. Pathol. 30, 969-985.
39. Chuang, V.P., Wallace, S., Soo, C.S., Charnsangavej, C. and Bowers, T. (1982). Therapeutic ivalon embolization of hepatic tumors. Am. J. Roentgenol. 138, 289-294.
40. Soo, C.S., Chuang, V.P., Wallace, S., Charnsangavej, C. and Carrasco, H. (1983). Treatment of hepatic neoplasm through extrahepatic collaterals. Radiology 147, 45-49.
41. Vassilopoulou-Sellin, R. and Ajani, J. (1994). Islet cell tumors of the pancreas. Endocrinol. Metab. Clin. North Am. 23, 53-65.